CC BY
35
□CSD*
International Journal of Endocrinology
OpuriHOAbHi AOCAigweHHq
/Original Researches/
UDK 616.366-002.616.376 DOI: 10.22141/2224-0721.16.3.2020.205268
Ayyildiz Civan H.1 , Papatya Qakir E.1 , Palabiyik F.1 , Comert M.2 3
1 Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
2 Istambul Medipol University, Medicine Faculty, Istanbul, Turkey
Effect of vitamin D and B12 levels on hepatosteatosis in overweight and obese children
For citation: Miznarodnij endokrinologicnij zurnal. 2020;16(3):209-214. doi: 10.22141/2224-0721.16.3.2020.205268
Abstract. Background. The childhood non-alcoholic hepatosteatosis leads to significant morbidity and mortality in adulthood. In recent years, vitamin D and B12 deficiency has been controversially associated with non-alcoholic fatty liver disease. Therefore, we aimed to evaluate the relationship of vitamin levels and insulin resistance (IR) with non-alcoholic hepatosteatosis in obese and overweight children. Material and methods. A total of 167 overweight and obese children aged 5-18 years were enrolled in this prospective study. The anthropometric measurements including body weight, height, body mass index (BMI) (weight/height2, kg/m2) were recorded. Children and adolescents with > 95th percentile of BMI for their age and gender were diagnosed with obesity, and BMI between the 85th and 94th percentiles was classified as overweight. Children and adolescents classified into two groups according to the presence of hepatosteatosis: normal liver and hepatosteatosis group. Additionally, hepatosteatosis grading was performed by ultrasonographic evaluation. Participants' demographic characteristics, physical examination, imaging and laboratory findings including serum levels of vitamin B12,25(OH)D analysis and insulin resistance index were documented and compared between groups. Results. One hundred and sixty-seven patients included in this study were: 103 (61.7 %) males, 64 (38.3 %) females, and the mean age of total participants was 11.48 ± 2.99 years. According to BMI-Z score, 26.3 % of individuals were defined as overweight and 73.7 % were obese. Hepatosteatosis was determined in 70.7 % (n = 118) of our cases and it was significantly higher in male patients (79.6 %) than in females (p = 0.001). Mean IR was statistically higher in non-alcoholic fatty liver disease group (11.15 ± 13.39) than in normal liver group (6.95 ± 6.20) (p = 0.029). Moreover, there were statistically significant differences found in IR levels according to severity of hepatosteatosis (p = 0.013). In addition, vitamin D and B12 deficiencies were not significantly associated with hepatosteatosis or severity of hepatosteatosis (p > 0.05). Also, no statistically significant differences were found in mean levels of vitamin D, vitamin B12 and IR between obese and overweight children. Conclusions. Our findings support the published data that vitamin D and B12 deficiencies do not contribute to the pathology of hepatosteatosis. In addition, insulin resistance has been demonstrated to be a risk factor for non-alcoholic fatty liver and hepatosteatosis severity.
Keywords: hepatosteatosis; non-alcoholic fatty liver disease; childhood obesity; vitamin B12 deficiency; vitamin D deficiency, insulin resistance
Introduction
The Centers for Disease Control and Prevention (CDC) reported (2015) a 2-fold increase in prevalence of childhood obesity and a 4-fold increase in adolescent obesity within the last 30 years [1]. Nonalcoholic fatty liver disease (NAFLD) is the most frequently reported chronic pediatric liver disease in children and adolescents. NAFLD preva-
lence appears to be increasing parallel to childhood obesity in recent years and it was reported in approximately 60 % of overweight children [2].
Although the pathophysiological mechanism of hepatocellular injury remains unclear, insulin resistance (IR) and metabolic syndrome are documented as risk factors in NAFLD. Long-term exposure to childhood-
© 2020. The Authors. This is an open access article under the terms of the Creative Commons Attribution 4.0 International License, CC BY, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
For correspondence: Hasret Ayyildiz Civan, MD, Department of Gastroenterology, Hepatology and Nutrition; Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey; contact phone:
+905057479765; e-mail: [email protected]
Full list of author information is available at the end of the article.
OpMNHOAbHi AOCAiA^eHHfl /Original Researches/
onset NAFLD is associated with significantly increased morbidity and mortality in adulthood due to severe hepatocellular damage and fibrosis [3]. Such that childhood NAFLD has been strongly associated with cirrhosis, hepatocellular carcinoma, end-stage liver disease and cardiovascular diseases in adults [4]. Although USG and serologic screening based on liver transaminases (AST, ALT, GGT) and inflammation markers (CRP) are frequently used, liver biopsy is the gold standard method in the diagnosis of hepatosteatosis which is often asymptomatic in childhood [3].
Vitamins D and B12 deficiency or insufficiency have been significantly associated with obesity, overweight, type 2 diabetes mellitus, metabolic syndrome, IR and cardiovascular disease in recent years [5—7]. It is well known that immunomodulatory and anti-inflammatory characteristics of vitamin D inhibits hepatic inflammation and fibrosis [8]. Moreover, low serum concentrations of 25-hydroxyvitamin D have been significantly associated with NAFLD and with or without non-alcoholic steatohepatitis (NASH) [9]. Similarly, vitamin B12 deficiency triggered hyperhomocysteinemia is significantly associated with NAFLD [10]. Furthermore, even the severity of hepatosteatosis was associated with vitamin D and B12 deficiency levels [10, 11]. On the contrary, there are published data concluded that vitamin deficiencies play no role in the etiopathology of hepatosteatosis [12]. Thus, the findings related to the vitamin deficiencies and hepatosteatosis seems to be controversial.
The purpose was to evaluate the relationship between vitamin levels and IR with non-alcoholic hepatosteatosis in obese and overweight children.
Materials and methods
This prospective study was performed with the Institutional Review Board protocol approval 04/03/2019 and number 2019/113 in Istanbul Training and Research Hospital, Department of Gastroenterology, Hepatology and Nutrition, between March 2019 — June 2019.
A total number of 167 overweight and obese children aged between 5—18 years old, were enrolled in present study. Children were enrolled in the study after obtainment of written informed consent from their family. The anthropo-metric measurements including body weight, height, BMI (weight/height2, kg/m2) were recorded. Body weight, height and BMI percentile were determined by using the growth curves of Turkish children [13]. Children and adolescents with a > 95th percentile of BMI for their age and gender were diagnosed with obesity, and BMIs between the 85th to 94th percentiles were classified as overweight.
Children and adolescents classified into two groups according to the presence of hepatosteatosis; absent hepatosteatosis group and hepatosteatosis group. Hepa-tosteatosis assessment performed by liver ultrasonography (Acuson S2000 Ultrasound system, Siemens, Germany). Additionally, hepatosteatosis grading was performed as follows:
Grade 0: Normal parenchymal liver echotexture.
Grade 1: Slightly increased liver echogenicity with normal visualization of vessel walls.
Grade 2: Moderately increased liver echotexture with impaired visualization of the vessel walls.
Grade 3: Severe increased liver echogenicity with poor visualization of the liver, portal vein borders and the diaphragm [14].
The serum levels of vitamin B12 and 25(OH)D analysis were performed using an immunodiagnostic system (Siemens, Advia Centaur xp, Germany) at a normality level of 220 pg/ml and 29.0 ng/ml, respectively. Biochemical analysis performed from serum samples by electro-chemilumi-nescence immunoassay analyzer (Beckman Coulter Unicel DXI 800). Haematological parameters were analysed using a haematology analyser (Cell-Dyne 3700, Abbott, Abbott Park, IL, USA). The insulin resistance index calculated according to the homeostasis model assessment of insulin resistance (HOMA-IR) formula; HOMA-IR = fasting serum insulin (microunits per milliliter) x fasting glucose (millimoles per liter)/22.5 [15]. Participants' demographic characteristics, physical examination, imaging and laboratory findings were documented and compared between groups.
Statistical analysis. All the data were analyzed with SPSS (Statistical Package for the Social Sciences) software for Windows (v21.0; IBM, Armonk, NY, USA). Individual and aggregate data were summarized using descriptive statistics including mean, standart deviations, medians (minmax), frequency distributions and percentages. Normality of data distribution was verified by Kolmogorov-Smirnov test. Comparison of the variables with normal distribution was made with Student t test. The variables which were not normally distributed, the Mann Whitney and Kruskal Wallis tests were conducted to compare between groups. Evaluation of categorical variables was performed by Chi-Square test. P-values of < 0.05 were considered statistically significant.
Results
The 167 patients included in this study were 103 (61.7 %) male, 64 (38.3 %) female and the mean age of total participants was 11.48 ± 2.99 (ranged = 3.36—17.92) years. Mean BMI-Z score was 2.36 ± 0.60 (ranged = 1,02-4,47). According to BMI-Z score, 26.3 % (n = 44) of the cases were defined as overweight (BMI-Z score = 1-2), and 73.7 % (n = 123) were obese (BMI-Z score > 2). Of the patients 36.5 % had comorbid diseases. The most common comorbid disease reported in our patients was gastritis with a percentage of 26.2 % and followed by esophageal reflux (13.1 %), constipation (11.5 %), and ADHD (8.2 %), respectively (table 1).
Hepatomegaly was the most frequent physical finding (72.5 %, n = 121), followed by hepatosplenomegaly (25.1 %, n = 42). Additionally, hepatosteatosis was determined in 70.7 % (n = 118) of our cases. Hepatoste-atosis was significantly higher in male patients (79.6 %) than females (56.3 %) (p = 0.001). Of the patients 81 had (68.6 %) grade 1 hepatosteatosis, 34 had (28.8 %) grade 2 hepatosteatosis and 3 had (2.6 %) grade 3 hepatosteatosis (table 1). Hepatosteatosis was detected in 70.5 % (n = 31) of overweight patients and 70.7 % (n = 87) of obese patients (p = 0.972).
iEI
OpurmoAbHi AOCAiA^eHHfl /Original Researches/
According to the evaluation of laboratory findings; mean levels of hemoglobin, ferritin, AST, ALT, GGT and triglyceride were statistically higher in NAFLD group than normal liver group (p-values = 0.002, 0.010, 0, 0, 0 and 0.008, respectively). Similarly, mean HDL was statistically lower in NAFLD group than normal liver group (p = 0,017).
In addition, mean IR was significantly higher in NAFLD group (11.15 ± 13.39) than normal liver group (6.95 ± 6.20) (p = 0.029). Vitamin D deficiency (< 20 ng/ml) and insufficiency (20—30 ng/ml) were found in 66.3 % (n = 108) and 23.9 % (n = 39) of all patients. Additionally, vitamin B12 deficiency (< 220 pg/ml) was detected in 37.0 % (n = 61) of patients. Vitamin D and B12 deficiencies were not significantly associated with hepatosteatosis (p-values = 0.958 and 0.153, respectively) (table 2).
Moreover, there were statistically significant differences found in IR levels according to severity of hepatosteatosis (p = 0.013). Mean IR was significantly increased particularly in grade 2 hepatosteatosis. In addition, vitamin D and B12 deficiencies were not significantly associated with severity of hepatosteatosis (table 3). There were also no
Table 1. Clinical characteristics of cases
Parameter Clinical Variables n (%)
Gender Female Male 64 (38.3) 103 (61.7)
BMI-Z Score Overweight (1-2) Obese (> 2) 44 (26.3) 123 (73.7)
USG Hepatomegaly Hepatosplenomegaly 121 (72.5) 42 (25.1)
Hepatosteatosis Absent Present 49 (29.3) 118 (70.7)
Hepatosteatosis severity Grade 1 Grade 2 Grade 3 81 (68.6) 34 (28.8) 3 (2.5)
Comorbid Diseases Gastritis Reflux Constipation ADHD Others 16 (26.2) 8 (13.1) 7 (11.5) 5 (8.2) 25 (41.0)
Table 2. Comparison of clinical features and laboratory outcomes between groups
Parameter Normal liver group (Mean ± SD) NAFLD group (Mean ± SD) P-value
BMI Z Score 2.33 ± 0.51 2.38 ± 0.63 0.618
HBA1c (%) 5.39 ± 0.30 5.45 ± 0.36 0.467
Glucose (mg/dL) 89.98 ± 7.36 90.79 ± 7.57 0.523
HOMA-IR 6.95 ± 6.20 11.15 ± 13.39 0.029*
Hemoglobin (g/dL) 12.82 ± 1.02 13.36 ± 1.02 0.002*
Ferritin (mg/L) 27.29 ± 16.55 37.70 ± 23.68 0.010*
Vitamin B12 (pg/mL) 306.71 ± 137.70 278.58 ± 164.20 0.153
Vitamin D (ng/ml) 19.33 ± 10.16 19.22 ± 10.58 0.958
AST (U/L) 23.67 ± 7.16 33.46 ± 17.95 0*
ALT (U/dL) 18.99 ± 10.25 44.80 ± 35.14 0*
GGT (U/L) 14.77 ± 4.96 25.22 ± 16.60 0*
LDL (mg/dl) 102.72 ± 53.30 102.42 ± 33.00 0.347
HDL (mg/dL) 48.34 ± 10.60 44.91 ± 12.00 0.017*
Triglyceride (mg/dl) 101.77 ± 76.80 122.76 ± 63.34 0.008*
Notes: here and the table 3:* — p < 0.05 statistically significant; SD — Standard Deviation.
Table 3. Comparison of vitamin D, vitamin B12 and IR levels according to the hepatosteatosis severity
Parameter Normal liver group (Mean ± SD) NAFLD group P-value
Grade 1 (Mean ± SD) Grade 2 (Mean ± SD) Grade 3 (Mean ± SD)
Vitamin D (ng/ml) 19.33 ± 10.16 18.80 ± 10.44 20.15 ± 11.09 20.20 ± 11.93 0.907
Vitamin B12 (pg/mL) 306.71 ± 137.70 280.94 ± 179.50 280.42 ± 130.80 195.66 ± 28.74 0.281
HOMA-IR 6.95 ± 6.20 9.77 ± 12.85 14.35 ± 14.68 11.57 ± 7.97 0.013*
OpumaAbHi gocAigweHHA /Original Researches/
JEI
Table 4. Comparison of vitamin D, vitamin B and IR levels according to the BMIZ Score
Parameter Overweight (Mean ± SD) Obese (Mean ± SD) P-value
Vitamin D (ng/ml) 18.21 ± 10.20 19.62 ± 10.52 0.439
Vitamin B12 (pg/mL) 262.70 ± 132.60 295.21 ± 164.10 0.089
HOMA-IR 7.85 ± 6.99 10.63 ± 13.10 0.330
statistically significant differences found in mean levels of vitamin D, vitamin B12 and IR between obese and overweight children (table 4).
Discussion
Despite the increasing prevalence of NAFLD in children and adolescents, there are estimated to be a large number of undiagnosed children due to the asymptomatic characteristics of the disease, the absence of standardized guidelines, invasive and expensive diagnostic procedures. Additionally, NAFLD primarily affects male gender [3]. J.A. Welsh et al. reported 3 times higher male prevalence in a study consisting of 14 918 children diagnosed with NAFLD in 20 years period [16]. V Nobili et al. documented the male percentage of 64 % in 73 children with NAFLD [11]. Similarly, children included in our study were 61.7 % male and 38.3 % female. Furthermore, hepatosteatosis was significantly higher (79.6 %) in male children.
Vitamin D deficiency or insufficiency has been significantly associated with increased BMI scores in published data. In addition, it is well known that obesity increases the risk of NAFLD. Therefore, the relationship between hepa-tosteatosis and childhood vitamin deficiencies has become an increasingly popular field of study in recent years with controversial findings [17]. G. Targher et al. reported significantly lower levels of 25(OH)D in histopathologically confirmed NAFLD children (n = 60) than healthy (n = 60) controls [18]. Similarly, in a meta-analysis consisting of 59 studies and 13 524 patients (5896 NAFLD and 7628 controls), researchers documented significantly lower serum 25(OH)D levels in NAFLD patients. Additionally, they noted a 1.26-fold (OR 1.26, 95% CI 1.15 to 1.38) increase in the prevalence of NAFLD associated with vitamin D deficiency. Thus, researchers concluded that vitamin D deficiency may play a role in the pathogenesis of NAFLD and NASH [19]. On the contrary, F. Dursun et al. has not significantly associated serum vitamin D deficiency or insufficiency with hepatosteatosis in 110 obese children [20]. Supportively, K. Katz et al. identified overweight and male gender as risk factors for hepatosteatosis, but not vitamin D deficiency in a study included 1630 adolescents [21]. In accordance with these data, vitamin D deficiency or insufficiency were not significantly associated with hepatosteatosis or severity of hepatosteatosis in present study.
Although decrease in serum B12 levels has been documented in acute hepatitis, cirrhosis and hepatocellular carcinoma, the relationship between vitamin B deficiency and NAFLD currently is not clear. There is limited number of published data with debated results evaluating vitamin B deficiency in NAFLD-patients. In a study, M. Koplay et al. compared 45 NAFLD patients with 30 healthy controls and
reported statistically increased ALT, decreased B12 and folate concentrations in the patient group. Researchers also highlighted significantly reduced vitamin B12 levels particularly in grade 2 and 3 hepatosteatosis [10]. A decrease in serum B12 levels in NAFLD patients was also demonstrated by F.F. Bolukbas et al. in a study comparing 129 patients diagnosed with NAFLD to 50 healthy controls [22]. On the other hand, S.A. Polyzos et al. have associated B12 deficiency with neither NAFLD nor severity of fibrosis in patients with histopathologically confirmed NAFLD. In the same study, significantly increased serum ALT, AST, IR, triglyceride and decreased HDL levels were also documented in NAFLD patients [23]. Similarly, S. Hirsch et al. have not associated B12 levels with NAFLD or liver damage in a study consisting of 43 obese women [24]. Supportively in our study, vitamin B12 deficiency or insufficiency were not significantly associated with hepatosteatosis or severity of hepatosteatosis.
It is unclear whether insulin resistance is a cause or a consequence of NAFLD. But IR related-liver fat accumulation is frequently reported and in some studies IR increase is defined as NAFLD feature even in non-obese patients [25]. J.F. Fu et al. divided 861 obese children (aged between: 6-16 years) into 3 groups; 'fatty liver — normal ALT', 'fatty liver — elevated ALT' and 'normal liver — normal ALT'. Researchers have revealed that IR was significantly increased in fatty liver groups [26]. Similarly, in a study conducted with 846 children, K. Tomi-naga et al. histopathologically confirmed the NAFLD diagnosis in 37 children and concluded that NAFLD was closely associated with metabolic syndrome and IR [27]. In a study conducted by A. Fraser et al. with 5586 adolescents, researchers demonstrated significantly increased serum ALT, CRP, triglyceride and IR levels in children with NAFLD [28]. In accordance with these data, mean serum levels of hemoglobin, ferritin, AST, ALT, GGT, triglyceride were statistically higher and mean HDL was statistically lower in NAFLD group than normal liver group in our study. Additionally, mean IR was statistically higher in NAFLD group than normal liver group. Moreover, it is remarkable that mean IR was significantly increased particularly in grade 2 hepatosteatosis.
Conclusions
Our findings support the published data that vitamin D and B12 deficiencies do not contribute to the pathology of hepatosteatosis. It should be considered that vitamin deficiency may occur particularly in obese pediatric population due to the already existing hepatocellular damage and fibro-sis. In addition, insulin resistance has been demonstrated to be a risk factor for non-alcoholic fatty liver and hepatosteatosis severity.
iEI_
Conflicts of interests. Authors declare the absence of any conflicts of interests and their own financial interest that might be construed to influence the results or interpretation of their manuscript.
Funding sources: none.
References
1. Centers for Disease Control and Prevention. Childhood obesity causes & consequences. 2016. Available from: https://www. cdc.gov/obesity/childhood/causes.html.
2. Bugianesi E, Bizzarri C, Rosso C, et al. Low Birthweight Increases the Likelihood ofSevere Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol. 2017;112(8):1277U1286. doi:10.1038/ajg.2017.140.
3. Dowla SA, Goss AM, Ashraf AP. Nonalcoholic Fatty Liver Disease in Children with Obesity. In: Debasis Bagchi, editor. Global Perspectives on Childhood Obesity. USA: Elsevier Science Publishing Co Inc; 2019. 255-268 pp.
4. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. doi:10.1001/ jama.2015.5370.
5. Mahammad SA, Nawaz SS, Marx KP, Siddiqu IA. Relationship between serum vitamin B12, hyperhomocysteinemia in nonalcoholic fatty liver disease. International Journal of Bioassays. 2013;2(11):1508-1510. doi:10.21746/ijbio.2013.11.0018.
6. Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):113-119. doi:10.1097/ MED.0b013e3283372859.
7. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J. 2008;7:4. doi:10.1186/1475-2891-7-4.
8. Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol. 2018;10(1):1420154. doi:10.4254/wjh.v10. i1.142.
9. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int J Clin Exp Med. 2015;8(10):17221-17234.
10. Koplay M, Gulcan E, Ozkan F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. JInvestigMed. 2011;59(7):1137D1140. doi:10.2310/JM.0b013e31822a29f5.
11. Nobili V, Giorgio V, Liccardo D, et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol. 2014;170(4):547D553. doi:10.1530/ EJE-13-0609.
12. Sezer OB, Buluq D, Hizli §, Andiran N, Yilmaz D, Ramadan SU. Low 25-hydroxyvitamin D level is not an independent risk factor for hepatosteatosis in obese children. J Pediatr Endocrinol Metab. 2016;29(7):7830788. doi:10.1515/jpem-2015-0426.
13. Neyzi O, Bundak R, Gokgay G, et al. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7(4):280U293. doi:10.4274/jcrpe.2183.
14. Shannon A, Alkhouri N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr. 2011;53(2):190D195. doi:10.1097/MPG.0b013e31821b4b61.
OpuriHOAbHi AOCAigweHHA /Original Researches/
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412U419. doi:10.1007/BF00280883.
16. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162(3):496D500.e1. doi:10.1016/j.jpeds.2012.08.043.
17. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004;158(6):531D537. doi:10.1001/ archpedi.158.6.531.
18. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):5170524. doi:10.1016/j.num-ecd.2006.04.002.
19. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int J Clin Exp Med. 2015;8(10):17221017234.
20. Dursun F, Gerenli N, Dur SMS, Kirmizibekmez H. The relationship between vitamin D level and hepatosteatosis in obese children. North Clin Istanb. 2018;6(1):28D32. doi:10.14744/ nci.2018.26097.
21. Katz K, Brar PC, Parekh N, Liu YH, Weitzman M. Suspected nonalcoholic Fatty liver disease is not associated with vitamin d status in adolescents after adjustment for obesity. J Obes. 2010;2010:496829. doi:10.1155/2010/496829.
22. Bolukbas FF, ignak S, Demirel OU, et al. Relationship between serum Vitamin B12 levels and hepatic fibrosis detected by transient elastography (Fibroscan) in non-alcoholic fatty liver disease. Anatolian Clinic the Journal of Medical Sciences. 2017;22(3):141-148. doi:10.21673/anadoluklin.297152
23. Polyzos SA, Kountouras J, Patsiaoura K, et al. Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. Int J Food Sci Nutr. 2012;63(6):659 U 666. doi:10.3109/09 637486.2011.649249.
24. Hirsch S, Poniachick J, Avendano M, et al. Serumfolate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition. 2005;21(2):1370141. doi:10.1016/j.nut.2004.03.022.
25. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544U1560. doi:10.3390/nu5051544.
26. Fu JF, Shi HB, Liu LR, et al. Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children?. World J Gastroenterol. 2011;17(6):735U742. doi:10.3748/wjg.v17.i6.735.
27. Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichika-wa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med. 2009;14(2):1420149. doi:10.1007/s12199-008-0074-5.
28. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133(6):1814U1820. doi:10.1053/j.gastro.2007.08.077.
Received 10.04.2020 Revised 24.04.2020 Accepted 03.05.2020 ■
Орипнальш дослiдження /Original Researches/
Information about authors
Hasret Ayyildiz Civan, MD, Department of Gastroenterology, Hepatology and Nutrition; Bakirköy Dr. Sadi KonukTraining and Research Hospital, Istanbul, Turkey; ORCID iD: https://orcid.org/0000-0002-5604-9722 Esra Papatya Çakir, MD, Department of Pediatric Endocrinology; Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey; ORCID iD: https://orcid.org/0000-0003-4664-7435 Figen Palabiyik, MD, Department of Pediatric Radiology; Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey; ORCID iD: https://orcid.org/0000-0003-0818-7650 Murat Cömert, MD, Department of Pediatric; Istambul Medipol University, medicine faculty, Istanbul, Turkey; ORCID iD: https://orcid.org/0000-0002-3554-7941
Ayyildiz Civan H.1, Papatya Qakir E.1, Palabiyik F.1, Comert M.2
1 Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
2 Istambul Medipol University, medicine faculty, Istanbul, Turkey
Вплив вмюту BiTOMiHiB D i B12 на частоту стеатогепатозу в д^ей i3 надмiрною масою лла та ожиршням
Резюме. Актуальтсть. Неалкогольний стеатогепатоз у д-тей призводить до зростання захворюваностi та смертностi в дорослому вЩ. Останн1м часом опублiкованi суперечливi данi стосовно взаемозв'язюв м1ж рiвнями вiтамiнiв В i В12 i частотою неалкогольного стеатогепатозу. Мета до^дження: оцшити зв'язок мiж рiвнем витамшв В i В12 та шсулшорези-стентнiстю (1Р) i частотою неалкогольного стеатогепатозу в дитей з ожиршням та на,амрною масою тiла. Матерiали та методи. У проспективне дослщження були включеш 167 да-тей iз надмiрною масою тiла та ожиршням вжом вщ 5 до 18 роив. Визначали антропометричнi показники, включаючи масу тiла, зрiст, шдекс маси тiла (1МТ) (вага/зрiст2, кг/м2). У дiтей i пiIдлiткiв з 1МТ > 95-го перцентиля для вжу i статi дiагностували ожиршня, а 1МТ вщ 85-го до 94-го перцентиля класифшували як надмрну масу тiла. Дiти та пвдлпки були розподiленi на дш групи: зi стеатогепатозом i без порушення функцюнального стану печiнки. Додатково оцшювали стан печiнки за допомогою ультразвукового дослщження. Визначали демографiчнi характеристики учасниюв дослщження, проводили загальноклшчний огляд, лабораторнi дослщження, включаючи аналiзи на виявлення рiвня виамшу В12 i 25(ОН) В у сироватщ кровi та визначення шдексу 1Р. Результати. 1з
167 обстежених 103 (61,7 %) були чоловiчоï стай, 64 (38,3 %) — жшочо*!, ïx середнiй bîk становив 11,48 ± 2,99 року. Згщно з 1МТ у 26,3 % випадюв була визначена надмiрна маса тша, а 73,7 % — ожиршня. Стеатогепатоз дiагностований у 70,7 % випадюв (n = 118), його частота була вiрогiдно вищою в пащен-тiв чоловiчоï статi (79,6 %), н1ж жшочо'! (p = 0,001). Середнiй показник 1Р був статистично вищим у груш дитей 3i стеатогепатозом (11,15 ± 13,39), н1ж у контрольны групi (6,95 ± 6,20) (р = 0,029). Крш того, установлен статистично значущi вщ-мшносп рiвнiв 1Р за ступенем вираженосп стеатогепатозу (р = 0,013). Не спостериалося вiрогiIдного взаемозв'язку м1ж дефщитом вiтамiнiв D та B12 i наявтстю та тяжистю стеатогепатозу (p > 0,05). Також не було виявлено статистично зна-чущих вщмшностей мiж середнiм вмiстом витамшв D i В12 та шдексом 1Р серед дiтей з ожиршням та на,аМрною масою тша. Висновки. Отримаш результати пщтверджують опублiкованi рашше данi про те, що дефщит вiтамiнiв D та B12 не сприяе розвитку стеатогепатозу в дпей iз надмiрною масою тiла та ожиршням. 1нсулшорезистентшсть е фактором ризику ви-никнення та прогресування стеатогепатозу. Ключовi слова: стеатогепатоз; дии; ожирiння; дефiцит вита-мiну В12; дефiцит вiтамiну D; iнсулiнорезистентнiсть
Ayyi ldiz Civan H.1, Papatya Qakir E.1, Palabiyik F.1, Comert M.2
1 Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
2 Istambul Medipol University, medicine faculty, Istanbul, Turkey
Влияние содержания витаминов D и B12 на частоту стеатогепатоза у детей
с избыточной массой тела и ожирением
Резюме. Актуальность. Неалкогольный стеатогепатоз у детей приводит к росту заболеваемости и смертности во взрослом возрасте. В последние годы опубликованы противоречивые данные о взаимосвязи между уровнями витаминов В и В12 и частотой неалкогольного стеатогепатоза. Цель исследования: оценить взаимосвязь между уровнем витаминов В и В12 и инсулинорезистентностью (ИР) и частотой неалкогольного стеатогепатоза у детей с ожирением и избыточной массой тела. Материалы и методы. В проспективное исследование были включены 167 детей с избыточной массой тела и ожирением в возрасте от 5 до 18 лет. Определяли антропометрические показатели, включая массу тела, рост, индекс массы тела (ИМТ) (вес/рост2, кг/м2). У детей и подростков с ИМТ > 95-го перцентиля для возраста и пола диагностировали ожирение, а ИМТ от 85-го до 94-го перцентиля классифицировали как избыточную массу тела. Дети и подростки были разделены на две группы: со стеатогепатозом и без нарушения функционального состояния печени. Дополнительно оценивали состояние печени с помощью ультразвукового исследования. Определяли демографические характеристики участников исследования, проводили общеклинический обзор, лабораторные исследования, включая анализы на выявление уровня витамина В12 и 25(ОН)В в сыворотке крови и определение
индекса ИР. Результаты. Из 167 обследованных 103 (61,7 %) были мужского пола, 64 (38,3 %) — женского, их средний возраст составил 11,48 ± 2,99 года. Согласно ИМТ в 26,3 % случаев была выявлена избыточная масса тела, а в 73,7 % — ожирение. Стеатогепатоз диагностирован в 70,7 % случаев (п = 118), его частота была достоверно выше у пациентов мужского пола (79,6 %), чем женского (р = 0,001). Средний показатель ИР был статистически выше в группе детей со стеатогепатозом (11,15 ± 13,39), чем в контрольной группе (6,95 ± 6,20) (р = 0,029). Кроме того, установлены статистически значимые различия уровней ИР по степени выраженности стеатогепатоза (р = 0,013). Не наблюдалось достоверной взаимосвязи между дефицитом витаминов В и В12, наличием и тяжестью стеатогепатоза (р > 0,05). Также не было выявлено статистически значимых различий между средним содержанием витаминов В и В12 и индексом ИР среди детей с ожирением и избыточной массой тела. Выводы. Полученные результаты подтверждают опубликованные ранее данные о том, что дефицит витаминов В и В12 не способствует развитию стеатогепатоза у детей с избыточной массой тела и ожирением. Инсулинорезистентность является фактором риска возникновения и прогрессирования стеатогепатоза. Ключевые слова: стеатогепатоз; дети; ожирение; дефицит витамина В12; дефицит витамина В; инсулинорезистентность
